Skip to search formSkip to main contentSkip to account menu

mRNA-derived Prostate Cancer Vaccine CV9104

Known as: CV9104, RNActive-derived Prostate Cancer Vaccine CV9104 
A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Self-adjuvanted RNActive® vaccines provide a promising platform for combination therapies with checkpoint inhibitors
Two-component mRNA vaccines (RNActive®) combine high antigen expression with strong immune stimulation. Intradermal injections of… 
2014
2014
Self-adjuvanted RNActive® vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
Two-component mRNA-based vaccine (RNActive®) combines high antigen expression with strong immune stimulation. We have previously… 
Review
2014
Review
2014
Letter from the Editor
Human Vaccines & Immunotherapeutics (HV&I) regularly puts a special focus on a current and interesting topic in the field of… 
2013
2013
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the…
Recently, the RNActive technology has been developed to generate highly active cancer vaccines. The antigen of choice is encoded… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)